Yep, Massey is correct, they have posted they will go into their...

Yep, Massey is correct, they have posted they will go into their first human clinical trial late 2014 (depending on regulatory conditions), probably first half 2015, so that is when we could expect a significant re-rate, and there are other incremental price inducements along the way, such as the selection of partners and the setting up of trials, along with tests on the quality of the stem cells.

Should be a good 18 months to 2 years, for investors to buy and hold a core of shares, and to also trade in and out with another parcel over the time frame.

Gw